CBD Research: A small knee-replacement trial found patients given 400 mg of prescription CBD used fewer opioids and reported less pain over 72 hours. The 800 mg dose showed no similar benefit, and researchers say larger studies are needed. Hemp Policy: A bipartisan bill would replace an approaching federal ban on most intoxicating hemp products with age limits, product restrictions and FDA oversight. Separately, medical cannabis companies say new DEA guidance could disrupt state-regulated markets. Medical Cannabis: UK registry data found patients with insomnia reported better sleep for up to two years after using prescribed cannabis products. In New Zealand, stigma has eased, but cost and doubts about GP prescribing remain barriers. Patient Access: Boots has launched a private medical cannabis service in the UK, offering another route for patients with long-term conditions.
AGP Executive Report
Your go-to archive of top headlines, summarized for quick and easy reading.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
CBD Clinical Guidance: A new review assesses cannabidiol’s potential benefits, biological targets, drug interactions and product-safety risks, as clinicians face growing patient interest but limited practical guidance. Hemp Rules: A federal crackdown set for Dec. 11 could sharply restrict hemp-derived THC products, putting pressure on retailers and processors; bipartisan senators have introduced the Hemp Guardrails Act as a regulatory alternative. Patient Access: Boots has launched a private medical cannabis service in the UK, offering prescriptions through online consultations for some long-term conditions. Health Risks: Research links cannabis use disorder with 57% higher odds of suicidal thoughts, while a separate study associates frequent use with more mild psychotic-like and depressive symptoms. These findings show associations, not proof that cannabis causes the symptoms.
Patient Access: Georgia has begun home delivery of medical cannabis for registered patients, though the USPS says marijuana remains nonmailable while it reviews whether federal rescheduling changes the rules. UK Care: Boots has launched a doctor-led private cannabis service for eligible adults with chronic pain, anxiety or insomnia, with specialist assessments and follow-up care. Regulatory Shift: Massachusetts regulators say federal guidance on medical cannabis rescheduling and DEA registration is still lacking, leaving businesses to seek their own legal advice. Product Safety: Studies and lab complaints raise concerns about missing cannabis label details and a pesticide-testing machine that allegedly failed to reliably detect harmful chemicals. CBD Industry: Ghana’s hemp and medical cannabis sectors featured at a Tokyo expo, where industry leaders discussed CBD research, quality standards and investment.
Medical Access: Georgia patients can now order state-approved medical cannabis for USPS delivery, expanding access for people who cannot easily reach a dispensary. In the UK, Boots is launching private medical cannabis prescriptions for conditions including pain, anxiety and insomnia, with online consultations. Product Safety: A Colorado study found only 14% of recreational cannabis products carried all labels required by state law; researchers also flagged missing freshness and storage information. Hemp THC Rules: New federal limits due Dec. 11 could sharply restrict intoxicating hemp-derived products. Veterans’ groups are urging Congress to regulate them rather than impose a broad ban. Health Risks: New reports link cannabis use disorder with higher odds of suicidal thoughts, while another study raises concern about cannabis use and earlier psychosis. These findings concern cannabis use, not CBD-specific treatments.
UK Medical Cannabis: Boots is launching a private prescription service through its online doctor, with reports pointing to treatment for conditions including chronic pain, anxiety and insomnia. Mental Health Research: In a retrospective study of 745 adults receiving transcranial magnetic stimulation for depression, cannabis users improved about as much as non-users; researchers also saw a drop in self-reported use during treatment. Cannabinoid Drug Development: MIRA Pharmaceuticals reported preclinical findings for MIRA-55, an investigational CB2-targeting compound for inflammatory pain. The company says it showed pain-relief and anti-inflammatory effects in preclinical testing; it is not an approved treatment. Psychosis Risk: A review of 149 studies involving more than 71,000 people found cannabis users who developed psychosis experienced its onset about 2.5 years earlier on average. The researchers noted the association does not prove cannabis caused the earlier onset. Hemp Policy: Veterans’ groups are urging Congress to replace an upcoming federal hemp-THC ban with regulation, warning a blanket prohibition could push consumers toward untested products.
UK Medical Access: Boots is launching Sure Leaf, the first medical cannabis prescription service from a UK high-street pharmacy. People aged 25 and over with chronic pain, anxiety or insomnia can apply after conventional treatments have failed; clinicians will assess applicants online and by video. Hemp Deadline: Kentucky’s CBD-focused growers and processors warn that a federal rule taking effect Dec. 11 could outlaw many hemp-derived products with more than trace THC unless Congress intervenes. The change could affect more than 100 licensed growers in the state. CBD Insomnia Trial: Australia’s Avecho Biotechnology has resumed recruitment for the final cohort of its late-stage trial of a CBD capsule for insomnia. An interim review backed continuing without expanding the study; a successful result could support an application to register an over-the-counter CBD product.
UK Medical Cannabis: Boots has launched SureLeaf, the first medical cannabis prescription service from a UK high street pharmacy. Adults aged 25 and over with chronic pain, anxiety or insomnia may be assessed after conventional treatments fail, with specialist review and follow-up. CBD Research: A clinical trial found cannabidiol did not ease severe behavioural problems in young people with intellectual disabilities; researchers say it should not be used for that purpose. Hemp Product Access: Patients say planned federal hemp-law changes due Dec. 11 could remove products they use to manage chronic conditions, as lawmakers debate tighter rules and consumer safety. Product Safety: A Colorado study found only one in seven cannabis products carried all required warnings, while more than half of flower products misrepresented THC levels.
UK Access: Boots has launched SureLeaf, an online medical cannabis service for patients aged 25 and over with chronic pain, anxiety or insomnia who have not responded to conventional treatments. Consultant assessments, independent clinical review and ongoing monitoring are included, alongside a University of Nottingham study of patient outcomes. CBD Medicine: Morocco’s first locally made cannabis-based medicine is now available in pharmacies for severe, treatment-resistant epilepsy. Its active ingredient is purified CBD, and the manufacturer plans exports after meeting domestic demand. Mental Health: A study of more than 415,000 U.S. adults found cannabis use disorder was linked to 57% higher odds of suicidal thoughts, a pattern that remained steady from 2014 to 2023.
Hemp Product Access: A 76-year-old says hemp gummies helped her insomnia and warns that federal restrictions due Dec. 11 could cut off access to products she relies on. Industry: eThekwini is advancing a three-year cannabis and hemp pilot to help local growers enter the formal market through training, quality genetics and regulatory guidance. Cannabinoid Research: Lab tests found cannabigerol’s anti-inflammatory effects on brain cells were inconsistent and dose-dependent, underscoring that early promise does not establish safety or benefit in people. Sleep Health: A long-term study found cannabis users had poorer objectively measured sleep, despite not reporting worse sleep themselves. Youth Health: A U.S. study found cannabis was involved in most substance-related emergency visits among adolescents and young adults, while alcohol predominated among older adults. Product Safety: A report says 86% of tested cannabis products lacked required label information, raising concerns about what consumers can learn from packaging.
CBG Safety: New lab research found cannabigerol’s anti-inflammatory effects on brain immune cells were inconsistent and depended on dose. Higher concentrations damaged cells, highlighting the need for more research before health claims are made. Sleep and Cannabis: A long-term study of 1,266 adults found cannabis users had poorer objectively measured sleep, despite not reporting worse sleep. Researchers said the findings do not support cannabis as a sleep aid. Youth Health: Cannabis was involved in most substance-related emergency visits among adolescents and young adults in a national study; alcohol was more common among older patients. Hemp Rules: Illinois has begun enforcing tighter limits on hemp-derived THC products, with a temporary pause for some businesses involved in a lawsuit. Separately, a new federal limit due in December could make many hemp-derived products illegal. Daily Use: Researchers estimate 1.2 million people in Great Britain use cannabis every day, with daily use more common among tobacco smokers and people not in work.
Cannabinoid Research: A new lab study found cannabigerol’s anti-inflammatory effects in brain immune cells were inconsistent. Higher concentrations caused cell stress, and most doses broke DNA in a cell-free test, underscoring the need for more research before treating it as a supplement. Illinois Hemp Rules: New limits classify consumable and topical products with more than 0.4 milligrams of total THC per container as cannabis. Enforcement is paused through Nov. 19 for some businesses in a federal lawsuit; licensed dispensaries expect more customers. Federal Restrictions: A separate federal limit due Dec. 11 could make about 95% of hemp-derived products illegal, according to an industry estimate, putting pressure on small retailers. Hemp Nutrition: Dietitians highlighted hemp seeds as a source of protein, fiber and antioxidant compounds, and suggested adding them to meals or snacks.
Product Safety: A Colorado study of 480 dispensary products found only one in seven had all required label information; just half of cannabis flower products listed accurate THC levels. Treatment Research: Morocco has launched its first cannabis-based epilepsy drug produced entirely in the country. Separately, a study found medical cannabis patients were twice as likely to stop prescription opioids, though the finding does not show cannabis caused the change. Health Risks: Recent studies also linked occasional cannabis use with higher stroke odds and prenatal cannabis use disorder with more postpartum psychiatric emergencies. These are associations, not proof of cause and effect.
CBD Medicine: Morocco’s Pharma 5 says it has developed the country’s first cannabis-based medicine, a highly purified CBD treatment for severe epilepsy that does not respond to standard therapies. The company says it controls production from regulated cultivation through manufacturing. Pain Care: A study reports that patients using medical cannabis were twice as likely to stop prescription opioids; separate research found cancer patients say cannabis helps ease symptoms. Market Growth: Australia’s medical cannabis market is forecast to exceed $2.6 billion by 2035, with hemp-based products making up the largest share. Hemp Rules: Missouri’s new law bars many intoxicating hemp-derived THC products from general retail, forcing some stores to clear shelves or close; Illinois retailers are challenging similar restrictions in court.
Hemp and CBD Rules: A looming federal hemp-product ban could catch some full-spectrum CBD products because of their trace THC. Illinois has already restricted intoxicating hemp products, but a court agreement temporarily shields some businesses until a Nov. 19 hearing; Missouri now requires a marijuana license to sell intoxicating hemp products. Consumer Safety: New Colorado research found only 14% of cannabis products carried all required warnings, while more than half of flower products misstated THC levels—raising concerns about whether shoppers can rely on labels. Heart Health: Preliminary survey research presented at an American Heart Association meeting linked occasional cannabis use with higher odds of a reported past stroke than non-use. The study cannot show that cannabis caused the strokes, and researchers found no steady rise in odds with more frequent use.
Hemp Rules: Illinois’ ban on intoxicating hemp products took effect Thursday, though about 300 businesses that sued have temporary protection until a Nov. 19 hearing. Federal restrictions on hemp-derived products are also set for Dec. 11, raising concerns about access and business survival. Patient Research: A Kentucky study found cancer patients using cannabis often reported relief from pain, nausea, anxiety and depression; the recent-use group was small, and researchers urge open conversations with clinicians. Separately, a study of chronic-pain patients linked medical cannabis use with higher rates of stopping long-term opioids, though it cannot establish cause and effect. Product Safety: Massachusetts regulators advanced rules to tighten cannabis testing, aiming for more reliable results and stronger public-health oversight.
Heart Health: A large U.S. study linked occasional cannabis use to 40% higher odds of a reported stroke; frequent use was linked to 25% higher odds. The findings show an association, not proof of cause. CBD Evidence: Oregon health officials’ updated review finds stronger support for pharmaceutical cannabinoids such as CBD for seizure disorders, while also flagging health risks associated with cannabis use. Product Rules: A federal hemp rule set for Dec. 11 could strip hemp status from products exceeding 0.4 milligrams of total THC per package, potentially changing which hemp-derived gummies remain available. Pregnancy: A California study found cannabis use disorder during pregnancy was associated with more psychiatric emergency visits in the year after birth; researchers caution the study does not establish cause and effect.
Hemp Product Rules: Most hemp-derived THC products face a federal limit of 0.4 milligrams per package starting Dec. 11, putting many products at risk of losing hemp status. Illinois has delayed enforcement for some businesses amid a lawsuit, while Philadelphia’s restrictions on intoxicating hemp products take effect Nov. 12. Pregnancy and Mental Health: A California study of more than 2 million births found that 10% of women diagnosed with cannabis use disorder during pregnancy visited an emergency department for psychiatric care in the year after delivery, compared with under 3% of women without a cannabis or alcohol use disorder. Medical Cannabis Research: A Senate committee urged the VA to study whether state medical cannabis programs are linked to reduced opioid use among veterans. CBD Safety: A cancer patient writing to a newspaper warned that cannabis products, including CBD oil, can be costly and may carry contamination risks; her experience underscores the need for reliable testing and medical guidance.
Hemp Rules: Illinois agreed to pause enforcement of its new hemp law against about 250 businesses until a Nov. 19 court hearing, offering a brief reprieve for sellers of CBD and hemp products. Separately, federal restrictions set for Dec. 11 could sharply limit THC in hemp-derived products, leaving retailers and consumers facing uncertainty. Medical CBD: MediPharm Labs launched a full-spectrum CBD oral oil in Brazil for medicinal use, manufactured at its Canadian facility and authorized by Brazil’s health regulator. Heart Health: Preliminary research presented at the American Heart Association’s 2026 meeting linked even occasional cannabis use with higher odds of stroke and other cardiovascular problems. The findings show an association, not proof that cannabis causes these outcomes, and do not establish the same risk for CBD.
Illinois Hemp Rules: The state agreed to pause enforcement of its new hemp law against businesses suing over it until at least Nov. 19. The law limits most hemp products with more than 0.4 milligrams of THC to cannabis dispensaries, putting some CBD and hemp retailers at risk. Federal Policy: A federal ban on intoxicating hemp products is set for Nov. 12, but a funding-bill carve-out delayed it. A report says hemp executive Bret Worley, son-in-law of former White House chief of staff Susie Wiles, deleted posts boasting of influence over the carve-out, raising questions about family ties and policy. Health Research: Studies reported this week linked cannabis use to higher stroke risk and increased mortality among people with alcohol-associated hepatitis; the findings show associations, not proof of cause.
Patient Access: South African medical cannabis patients say a reported freeze on new Section 21 approvals has cut off legal treatment for people with epilepsy and serious neurological conditions, after regulators moved against alleged abuse of the system. Hemp Rules: A Texas appeals court postponed arguments over state restrictions on hemp-derived THC products, leaving the challenge for three newly elected Democratic justices to hear after they take office. Texas Reform: Sen. Carol Alvarado filed a bill to legalize and regulate adult-use cannabis, while incoming Lt. Gov. Vikki Goodwin says lawmakers are weighing broader legalization or an expansion of the state’s medical program. Medical Research: India’s CSIR-IIIM cannabis project is exploring medicines for pain, cancer, epilepsy and other conditions; officials say the work is for medical and research use. Health Risks: A study links cannabis use with higher mortality among patients hospitalized for alcohol-associated hepatitis, underscoring the need for clinicians to assess substance use. Federal Guidance: Congressional researchers criticized the FDA for being nine months late in publishing legally required guidance on hemp products.
Sign up for:
Cannabidiol Healthcare News
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.